Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells 11,581 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 11,581 shares of the business’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $29.26, for a total value of $338,860.06. Following the transaction, the chief financial officer now directly owns 124,104 shares of the company’s stock, valued at approximately $3,631,283.04. This represents a 8.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, February 10th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $43.01, for a total transaction of $498,098.81.
• On Tuesday, February 4th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $38.92, for a total value of $450,732.52.
• On Monday, January 13th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $24.44, for a total value of $283,039.64.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $25.93 on Friday. Hims & Hers Health, Inc. has a 1-year low of $11.20 and a 1-year high of $72.98. The business’s fifty day moving average price is $39.82 and its 200 day moving average price is $29.84. The firm has a market capitalization of $5.76 billion, a PE ratio of 58.93 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on HIMS. Canaccord Genuity Group upped their price target on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Needham & Company LLC increased their target price on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. Citigroup restated a “sell” rating and issued a $27.00 price objective on shares of Hims & Hers Health in a research note on Thursday, March 6th. Bank of America lifted their target price on Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a research report on Tuesday, March 18th. Finally, BTIG Research began coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price for the company. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $37.31.

Institutional Trading of Hims & Hers Health

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of Hims & Hers Health by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after acquiring an additional 2,020,722 shares in the last quarter. Farallon Capital Management LLC lifted its stake in Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after buying an additional 8,364,000 shares during the last quarter. Renaissance Technologies LLC lifted its position in Hims & Hers Health by 29.0% in the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock valued at $168,079,000 after purchasing an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after buying an additional 4,145,305 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Hims & Hers Health by 4.7% in the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after purchasing an additional 206,078 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.